Clinical Characteristics of Hepatitis in Pregnancy in Pregnant Women with Chronic Hepatitis B Virus Infection and Evaluation of the Efficacy of Antiviral Therapy

Abstract

To explore the clinical characteristics of hepatitis in pregnant women with chronic hepatitis B virus infection and the efficacy of telbivudine treatment is the main objective. In this study, 136 pregnant women with hepatitis B virus infection diagnosed in our hospital from March 2017 to December 2018 were selected as the research objects. According to whether the patients had hepatitis episodes, they were divided into 96 cases in the seizure group and 40 cases in the non-seizure group. The two groups of patients were compared. The difference of serum alanine aminotransferase, aspartate aminotransferase, hepatitis B virus-deoxyribonucleic acid load, hepatitis B surface antigen, hepatitis B e antigen; randomize the attack group of patients and divide into telbivudine group and entecavir group with 48 cases each. Compare hepatitis B virus-deoxyribonucleic acid load, hepatitis B surface antigen, hepatitis B e antigen, serum alanine aminotransferase, aspartate aminotransferase changes at different times before and after treatment and peripheral blood T helper cell factors and regulatory T cells/T helper 17 cells levels changes and shows differences in neonatal outcomes. The hepatitis B virus-deoxyribonucleic acid load, hepatitis B surface antigen, hepatitis B e antigen, serum alanine aminotransferase and aspartate aminotransferase levels of the hepatitis attack group were higher than those of the non-seizure group and the difference was statistically significant (p 0.05), after 12 w of treatment, the hepatitis B virus-deoxyribonucleic acid load, hepatitis B surface antigen, hepatitis B e antigen, serum alanine aminotransferase and aspartate aminotransferase levels were not statistically significant (p>0.05). The levels of hepatitis B virus-deoxyribonucleic acid load, hepatitis B surface antigen, hepatitis B e antigen, serum alanine aminotransferase and aspartate aminotransferase in the telbivudine group were lower than those in the entecavir group and the difference was statistically significant (p 0.05). After 12 w of treatment, the levels of interferon gamma and interleukin-2 in the telbivudine group were higher than those in the entecavir group. The difference was statistically significant (p 0.05). The main time for the onset of hepatitis in pregnant women with hepatitis B virus infection is the second trimester. The liver function and hepatitis B virusdeoxyribonucleic acid load of hepatitis B virus infected pregnant women with hepatitis are more serious